{"id":389048,"date":"2020-11-27T08:33:15","date_gmt":"2020-11-27T13:33:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389048"},"modified":"2020-11-27T08:33:15","modified_gmt":"2020-11-27T13:33:15","slug":"usan-modifies-lead-drug-candidates-chemical-name-to-simufilam","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/","title":{"rendered":"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019"},"content":{"rendered":"

\nFuture References to Lead Drug Candidate for Alzheimer\u2019s Disease Will Be Simufilam
\n<\/h2>\n
\n

\n AUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) — <\/strong>Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company\u2019s lead drug candidate to \u2018simufilam.\u2019 This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East.<\/p>\n

USAN has accepted WHO\u2019s advice. Future references to Cassava Sciences\u2019 lead drug candidate for Alzheimer\u2019s disease will be simufilam.<\/p>\n

\n About USAN<\/strong>
\n
The United States Adopted Names Council is responsible for selecting simple, informative and unique nonproprietary drug names. The USAN Council establishes logical nomenclature classifications based on pharmacological or chemical relationships. In addition to one member-at-large and a U.S. Food and Drug Administration liaison, USAN consists of one representative from The American Medical Association, the United States Pharmacopeia<\/a>\u00a0and the American Pharmacists Association<\/a>.<\/p>\n

\n About Alzheimer’s Disease<\/strong>
\n
Alzheimer\u2019s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer\u2019s disease, much less reverse its course. In the U.S. alone, approximately 5.8 million people are currently living with Alzheimer\u2019s disease, and approximately 487,000 people age 65 or older developed Alzheimer\u2019s in 2019. The number of people living with Alzheimer\u2019s disease is expected to grow dramatically in the years ahead, resulting in a growing social and economic burden.<\/p>\n

\n About <\/strong>
\n Simufilam<\/strong>
\n
Simufilam is Cassava Sciences\u2019 lead therapeutic product candidate for the treatment of Alzheimer\u2019s disease. Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer\u2019s pathology, neurodegeneration and neuroinflammation. The underlying science is published in peer-reviewed scientific journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer\u2019s Disease.<\/p>\n

\n About Cassava Sciences, Inc.<\/strong>
\n
Cassava Sciences\u2019 mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer\u2019s disease. For more information, please visit: https:\/\/www.CassavaSciences.com<\/a><\/p>\n

\n For More Information Contact:<\/strong>
\n
Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.
eschoen@CassavaSciences.com
<\/a>(512) 501-2450<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Future References to Lead Drug Candidate for Alzheimer\u2019s Disease Will Be Simufilam AUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company\u2019s lead drug candidate to \u2018simufilam.\u2019 This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO\u2019s advice. Future references to Cassava Sciences\u2019 lead drug candidate for Alzheimer\u2019s disease will be simufilam. About USAN The United States Adopted Names Council is responsible for selecting simple, informative and unique nonproprietary drug names. The USAN Council establishes logical nomenclature classifications based … <\/p>\n

Continue reading “USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389048","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nUSAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Future References to Lead Drug Candidate for Alzheimer\u2019s Disease Will Be Simufilam AUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company\u2019s lead drug candidate to \u2018simufilam.\u2019 This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO\u2019s advice. Future references to Cassava Sciences\u2019 lead drug candidate for Alzheimer\u2019s disease will be simufilam. About USAN The United States Adopted Names Council is responsible for selecting simple, informative and unique nonproprietary drug names. The USAN Council establishes logical nomenclature classifications based … Continue reading "USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-27T13:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019\",\"datePublished\":\"2020-11-27T13:33:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/\"},\"wordCount\":411,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/\",\"name\":\"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=\",\"datePublished\":\"2020-11-27T13:33:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/","og_locale":"en_US","og_type":"article","og_title":"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019 - Market Newsdesk","og_description":"Future References to Lead Drug Candidate for Alzheimer\u2019s Disease Will Be Simufilam AUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company\u2019s lead drug candidate to \u2018simufilam.\u2019 This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO\u2019s advice. Future references to Cassava Sciences\u2019 lead drug candidate for Alzheimer\u2019s disease will be simufilam. About USAN The United States Adopted Names Council is responsible for selecting simple, informative and unique nonproprietary drug names. The USAN Council establishes logical nomenclature classifications based … Continue reading \"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-27T13:33:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019","datePublished":"2020-11-27T13:33:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/"},"wordCount":411,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/","name":"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=","datePublished":"2020-11-27T13:33:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mjk2MCMzODQ1ODY0IzIwMjc4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/usan-modifies-lead-drug-candidates-chemical-name-to-simufilam\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"USAN Modifies Lead Drug Candidate\u2019s\u00a0Chemical Name to \u2018Simufilam\u2019"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389048"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389048\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}